Xuanfei Baidu granule alleviates coronavirus-induced pneumonia in low-temperature and high-humidity environments
Qianru Zhao, Ronghua Zhao, Zihan Geng, Lei Bao, Shanshan Guo, Yu Wang, Xiaolan Cui
Xuanfei Baidu granule alleviates coronavirus-induced pneumonia in low-temperature and high-humidity environments
Objective: Our study aimed to investigate the action of Xuanfei Baidu granules (XFBD) and their mechanism of action in a model of coronavirus pneumonia under cold and damp conditions.
Methods: A total of 60 Bagg Albino (BALB/c) mice were randomly assigned to different groups, including the control, model, low-dose XFBD (1.84 g/kg), medium-dose XFBD (3.67 g/kg), and high-dose XFBD (7.34 g/kg) groups. To simulate the model of coronavirus infection, a combination of cold and damp stimuli and coronavirus strain 229E (CoV 229E) was employed. Subsequently, XFBD was administered on the fifth day and lasted for 3 days. To evaluate the efficacy of XFBD in BALB/c mice, various parameters, including behavior, lung index, viral load, and pulmonary pathology, were observed. Levels of interleukin-6 (IL-6), interleukin-10 (IL-10), and tumor necrosis factor-α (TNF-α) were measured using enzyme-linked immunosorbent assay (ELISA). The fractions of CD4+ T cells, CD8+ T cells, and B cells were measured using flow cytometry.
Results: The mice in the control group were active, in good condition, and exhibited shiny hair. After modeling, the mice demonstrated less activity, low energy levels, messy and less shiny hair, poor appetite, and soft stools. The symptoms of coronavirus pneumonia were all significantly improved after the administration of different doses of XFBD. At three dosage levels, XFBD effectively increased gastrin (GAS) content, whereas medium and high doses of XFBD reduced motilin (MTL) content. The high-dose XFBD group showed a significant reduction in pathological damage to lung tissue. Treatment with three doses of XFBD demonstrated significant downregulation of inflammatory factors and regulation of CD4+ and CD8+ T cell and B cell expression. The high-dose XFBD group exhibited enhanced efficacy compared to the other doses.
Conclusions: XFBD showed a therapeutic effect on coronavirus pneumonia under cold and damp conditions, improved the behavioral characterization and gastrointestinal index, and reduced the lung virus titer and histopathology. This may be associated with the inhibition of inflammation and an increase in the number of lymphocytes.
Chinese medicine / Coronavirus / Inflammation / Xuanfei Baidu granule
[[1]] |
Hasoksuz M, Kilic S, Sarac F. Coronaviruses and SARS-COV-2. Turk J Med Sci 2020;50(SI-1):549-556.
|
[[2]] |
Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019;17(3):181-192.
|
[[3]] |
Tang G, Liu Z, Chen D. Human coronaviruses: origin, host and receptor. J Clin Virol 2022;155:105246.
|
[[4]] |
Heimdal I, Lysvand H, Krokstad S, et al. Detection of subgenomic mRNA from endemic human coronavirus OC43 and NL63 compared to viral genomic loads, single virus detection and clinical manifestations in children with respiratory tract infections. J Clin Virol 2022;154:105247.
|
[[5]] |
Chan JF, To KK, Tse H, et al. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol 2013;21(10):544-555.
|
[[6]] |
Adedokun KA, Olarinmoye AO, Mustapha JO, et al. A close look at the biology of SARS-CoV-2, and the potential influence of weather conditions and seasons on COVID-19 case spread. Infect Dis Poverty 2020;9(1):77.
|
[[7]] |
Shephard RJ. Immune changes induced by exercise in an adverse environment. Can J Physiol Pharmacol 1998;76(5):539-546.
|
[[8]] |
Xu H. Research status and development trend on related characteristics of coronavirus. J Chaohu College 2020;22(3):1-8.
|
[[9]] |
Ge H, Wang YF, Xu J, et al. Anti-influenza agents from Traditional Chinese Medicine. Nat Prod Rep 2010;27(12):1758-1780.
|
[[10]] |
Liu QQ, Zhang HC, Wang CX, et al. Expert consensus on the clinical application of Xuanfei Baidu granule. Acupunct Herb Med 2023;3(1):1-6.
|
[[11]] |
Huang K, Zhang P, Zhang Z, et al. Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: efficacies and mechanisms. Pharmacol Ther 2021;225:107843.
|
[[12]] |
Wang Y, Wang X, Li Y, et al. Xuanfei Baidu Decoction reduces acute lung injury by regulating infiltration of neutrophils and macrophages via PD-1/IL17A pathway. Pharmacol Res 2022;176:106083.
|
[[13]] |
Wang Y, Sang X, Shao R, et al. Xuanfei Baidu Decoction protects against macrophages induced inflammation and pulmonary fibrosis via inhibiting IL-6/STAT3 signaling pathway. J Ethnopharmacol 2022;283:114701.
|
[[14]] |
Li Z, Pan H, Yang J, et al. Xuanfei Baidu formula alleviates impaired mitochondrial dynamics and activated NLRP3 inflammasome by repressing NF-kappaB and MAPK pathways in LPS-induced ALI and inflammation models. Phytomedicine 2023;108:154545.
|
[[15]] |
Kong L, Deng J, Zhou X, et al. Sitagliptin activates the p62-Keap1-Nrf2 signalling pathway to alleviate oxidative stress and excessive autophagy in severe acute pancreatitis-related acute lung injury. Cell Death Dis 2021;12(10):928.
|
[[16]] |
Cronkite DA, Strutt TM. The regulation of inflammation by innate and adaptive lymphocytes. J Immunol Res 2018;(2018):1-14.
|
[[17]] |
Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 2021;184(4):861-880.
|
[[18]] |
Zheng Y, Jin D, Lin J, et al. Understanding COVID-19 in Wuhan from the perspective of cold-dampness: clinical evidences and mechanisms. Front Med (Lausanne) 2021;8:617659.
|
[[19]] |
Guo SS, Li D, Shi YJ, et al. Efficacy evaluation of Jinchai Kangbingdu capsule based on coronaryvirus pneumonia with “Hanshi Yidu Xifei” syndrome model. Chin J Exp Tradit Med Form 2020;26(13):1-7.
|
[[20]] |
Lammermann T, Afonso PV, Angermann BR, et al. Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo. Nature 2013;498(7454):371-375.
|
[[21]] |
Kang SJ, Liang HE, Reizis B, et al. Regulation of hierarchical clustering and activation of innate immune cells by dendritic cells. Immunity 2008;29(5):819-833.
|
[[22]] |
Rivera A, Siracusa MC, Yap GS, et al. Innate cell communication kick-starts pathogen-specific immunity. Nat Immunol 2016;17(4):356-363.
|
[[23]] |
Zhao L, Liu H, Wang Y, et al. Multimodal identification by tran- scriptomics and multiscale bioassays of active components in Xuanfeibaidu formula to suppress macrophage-mediated immune response. Engineering (Beijing) 2021;20:63-76.
|
[[24]] |
Li X, Wichai N, Wang J, et al. Regulation of innate and adaptive immunity using herbal medicine: benefits for the COVID-19 vaccination. Acupunct Herb Med 2022;2(3):196-206.
|
/
〈 | 〉 |